1. Quartilho A, Simkiss P, Zekite A, Xing W, Wormald R, Bunce C. Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013. Eye. 2016;30:602–7.
2. GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD). ClinicalTrials.gov [online]. https://clinicaltrials.gov/ct2/show/NCT03815825?term=geographic+atrophy&recrs=adf&cond=Age-related+Macular+Degeneration&draw=2&rank=5. Accessed 6 July 2020.
3. Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular. ClinicalTrials.gov [online]. https://clinicaltrials.gov/ct2/show/NCT04339764?term=geographic+atrophy&recrs=adf&cond=Age-related+Macular+Degeneration&draw=2&rank=2. Accessed 6 July 2020.
4. Finger RP, Schmitz-Valckenberg S, Schmid M, Rubin GS, Dunbar H, Tufail A, et al. MACUSTAR: development and clinical validation of functional, structural, and patient-reported endpoints in intermediate age-related macular degeneration. Ophthalmologica. 2019;241:61–72.
5. Ambati J, Fowler BJ. Mechanisms of age-related macular degeneration. Neuron. 2012;75:26–39.